fda glp-1 warning september 2025 news FDA Says to Drop Suicide Warning From GLP-1 Drug Labels

Attorney General Jeff Jackson and Bipartisan Coalition Urge FDA to Take Action Against Counterfeit Drug Sellers

23.34

★★★★☆4.8 (126)

Pharmacovigilance Assessment of Compounded GLP-1 Receptor Agonists: Insights From the FDA Adverse Event Reporting System

20.07

★★★★★4.9 (98)

The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight-loss results, Retatrutide

27.15

★★★★★5.0 (157)

What Patients Need to Know About the GLP-1 FDA Policy Changes

22.62

★★★★★4.7 (84)

Today, the FDA established a “green list” import alert to help stop potentially dangerous GLP-1 active pharmaceutical ingredients from unverified foreign sources from entering the U.S. market. The agency will continue to

25.55

★★★★★4.9 (203)

The FDA Just Flagged Ozempic. Your Body Already Has a Better Answer

25.60

★★★★★5.0 (176)

FDA Targets GLP-1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling

29.93

★★★★★4.8 (132)